SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 3,128 Shares

Key Points

• SiBone SVP Michael Pisetsky sold 3,128 shares of stock at an average price of $14.25, totaling $44,574, and now owns 255,224 shares.
• The company's recent earnings report showed an EPS of ($0.14), beating estimates, with revenue of $48.63 million for the quarter.
• Analysts have provided a consensus rating of "Moderate Buy" for SiBone, with an average target price of $23.67.

SiBone (NASDAQ:SIBN - Get Free Report) SVP Michael Pisetsky sold 3,128 shares of the firm's stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $14.25, for a total transaction of $44,574.00. Following the completion of the transaction, the senior vice president directly owned 255,224 shares of the company's stock, valued at approximately $3,636,942. This trade represents a 1.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

SiBone Stock Performance

SIBN traded down $0.01 on Monday, hitting $14.49. The company's stock had a trading volume of 446,171 shares, compared to its average volume of 422,885. The company's 50 day simple moving average is $15.76 and its 200-day simple moving average is $16.28. The firm has a market cap of $625.10 million, a P/E ratio of -25.87 and a beta of 0.83. SiBone has a 12 month low of $11.70 and a 12 month high of $20.05. The company has a quick ratio of 7.00, a current ratio of 8.38 and a debt-to-equity ratio of 0.21.

SiBone (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. The firm had revenue of $48.63 million during the quarter, compared to the consensus estimate of $48.12 million. SiBone has set its FY 2025 guidance at EPS. Analysts forecast that SiBone will post -0.78 EPS for the current year.

Institutional Investors Weigh In On SiBone

Several large investors have recently added to or reduced their stakes in the stock. Johnson Investment Counsel Inc. acquired a new position in shares of SiBone in the 1st quarter valued at $148,000. Rhumbline Advisers boosted its stake in SiBone by 3.6% in the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company's stock valued at $838,000 after buying an additional 2,100 shares in the last quarter. GAMMA Investing LLC raised its position in SiBone by 20,352.6% in the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after purchasing an additional 3,867 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in shares of SiBone by 7.7% during the second quarter. Harbor Capital Advisors Inc. now owns 573,705 shares of the company's stock worth $10,797,000 after acquiring an additional 40,993 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in SiBone by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company's stock valued at $5,328,000 after purchasing an additional 83,919 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SiBone in a research note on Saturday, September 27th. Cantor Fitzgerald set a $25.00 target price on shares of SiBone and gave the company an "overweight" rating in a research note on Monday, August 11th. Finally, Wall Street Zen lowered shares of SiBone from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, SiBone currently has a consensus rating of "Moderate Buy" and an average target price of $23.67.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.